【CSCO 2022 Preview】Professor Qin Shukui leads the domestic multi-center pancreatic cancer drug treatment research

Pancreatic cancer is a malignant tumor of the digestive system that is very difficult to diagnose and treat, and research progress has been slow, commonly known as the "king of cancers"
.
In recent years, the incidence and mortality of pancreatic cancer have shown an upward trend
.
In 2020, there were 495773 new cases of pancreatic cancer and 466003 deaths worldwide; Among them, China has 124994 cases (25.
2%) and 121853 cases (26.
1%)
, respectively.

Because pancreatic cancer has the characteristics of high degree of malignancy, insidious onset, atypical early symptoms, etc.
, it is often diagnosed in the middle and advanced stages, rapid progression, and poor prognosis, and the 5-year survival rate of patients is only 7%-9%.

Surgical resection is the most important treatment for pancreatic cancer, but the benefits of surgery alone are relatively limited
.
Because about 25% of pancreatic cancer patients who come to the hospital are locally advanced, the median survival (mOS) is only 9 months; While 60% have already transferred, mOS is only 6 months old; Only 15-20% of patients are suitable for surgical resection at the initial diagnosis, and even then, there may be recurrence and metastasis after surgery, and mOS in operable patients is only about
20 months.

The treatment of pancreatic cancer mainly depends on drug treatment, but at present, the first-line standard treatment options for pancreatic cancer are very limited, and in the second-line treatment, in addition to choosing gemcitabine-based or 5-FU-based regimens that are not used in first-line treatment, there is almost no drug available
.

The HR-IRI-APC study is a national multicenter, randomized, double-blind, controlled phase III clinical study led by Chinese experts, which explored the efficacy and safety
of HR070803 (liposomal irinotecan hydrochloride) combined with fluorouracil (5-FU)/folinic acid (LV) regimen for unresectable locally advanced pancreatic cancer (LAPC) or metastatic pancreatic cancer (mPC) after first-line gemcitabine treatment failure.

The study, led by Professor Qin Shukui of the Eastern Theater General Hospital and Professor Wang Liwei of Renji Hospital, showed that HR070803 combined with 5-FU/LV regimen was used for unresectable lapc or mPC after first-line gemcitabine treatment failure significantly prolonged median OS (7.
39 months vs.
4.
99 months) and median PFS (4.
21 months vs.
1.
48 months) in the placebo group, significantly reducing the risk of
disease death and progression 。 This is the first clinical study of irinotecan hydrochloride liposomal injection combined with 5-FU/LV second-line treatment of advanced pancreatic cancer completely for Chinese group and obtained positive results, which appeared on the ESMO international stage on September 10 this year and received extensive attention
from international colleagues.

On November 5, 2022, Professor Qin Shukui will give a conference report on "HR070803 combined with 5-FU/LV in the treatment of advanced pancreatic cancer after gemcitabine treatment failure" at the CSCO Annual Conference, to analyze in detail the current results
of this important study.
HR070803, as the first drug independently developed in China to carry out phase III clinical research on the second-line treatment of pancreatic cancer, is expected to become the standard treatment plan for second-line treatment of advanced pancreatic cancer, bringing new choices
to Chinese pancreatic cancer patients.

Resources:

https://mp.
weixin.
qq.
com/s/oIWxcuHy_N6CgHnTX3A7Wg

https://mp.
weixin.
qq.
com/s/37HPYx8yBF5RcgkRVk8WCg

https://mp.
weixin.
qq.
com/s/anoTZl6klgictFJr_ZDv7g